...mos of LHRH analog plus anti-androgen followed by an "off treatment" interval determined by the rise in PSA to an arbitr...
...mos (range 0.9-6.3); median OS=12.6 mos (range 2.8-24.9). A Pt with GB who gained PR has a PFS of 5.4+ mos. Two of 3 PTS...
...mOS was 172 days (range 28-607+), OS at 6 months was 50% and OS at 12 months was 14.3%. G3-4 toxicities consisted in: G3...
...mos. vs. 23 mos, p=0.003). Adjuvant CTx was not beneficial in patients with N- disease.,LNI was an independent prognosti...
...mos) (1.5-26.5) and median overall survival was 12.5 mos (2.5-47.5). With minimum follow-up of 13 mos, 12/37 (32%) pts h...
...mos, and are planned for 2 yrs. Anxiety levels were compared pairwise in pts at baseline (prior to the initiation of the...
...mos) (95% CI:4-8). Median TTP and OS were 3 mos (95% CI: 2-4) and 6 mos (95% CI:4-9). Pre-treatment biopsies revealed th...
...mos. (95% CI, 5.5-14.8), for those demonstrating PR/SD 14.8 mos (95% CI, 11.4-27.4). Myelosuppression was the major toxi...
...MOS was similar in both regimens (CAP: 14.2 m vs. CIV 5-FU: 14.9 m). Grade 3/4 hematologic toxicity was more frequent in...
...mos (2-sided unstratified log-rank test; significance level 0.05). A prospectively planned interim analysis will be perf...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
